Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > ICOS

ICOS

Brief Information

Name:Inducible T-cell costimulator
Target Synonym:Activation-inducible lymphocyte immunomediatory molecule,Inducible T-cell costimulator,ICOS,CD278,AILIM,Inducible T Cell Costimulator,Inducible T-Cell Co-Stimulator,Inducible Costimulator,CD278 Antigen,CVID1,Inducible T-Cell Co-Stimulator Protein
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Part of Bioactivity data

ICS-M52H8-ELISA
Mouse ICOS (C137S, C138S), His TagMouse ICOS (C137S, C138S), His Tag (Cat. No. ICS-M52H8) ELISA bioactivity

Immobilized Human B7-H2, Fc Tag (Cat. No. B72-H5254) at 5 μg/mL (100 μL/well) can bind Mouse ICOS (C137S, C138S), His Tag (Cat. No. ICS-M52H8) with a linear range of 39-625 ng/mL (QC tested).

ICS-M5259-ELISA
Mouse ICOS (C137S, C138S), Fc TagMouse ICOS (C137S, C138S), Fc Tag (Cat. No. ICS-M5259) ELISA bioactivity

Immobilized Human B7-H2, His Tag (Cat. No. B72-H5221) at 1 μg/mL (100 μL/well) can bind Mouse ICOS (C137S, C138S), Fc Tag (Cat. No. ICS-M5259) with a linear range of 0.3-10 ng/mL (QC tested).

Synonym Name

ICOS,CD278,AILIM,Inducible T-cell costimulator

Background

Inducible T-cell costimulator (ICOS) is also known as Activation-inducible lymphocyte immunomediatory molecule (AILIM), CD278, which belongs to the CD28 family of immune costimulatory receptors consisting of CD28, CTLA-4 and PD-1. ICOS enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. CD278 / ICOS prevents the apoptosis of pre-activated T-cells and also plays a critical role in CD40-mediated class switching of immunoglobin isotypes.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Vopratelimab JTX-2011 Phase 2 Clinical Jounce Therapeutics Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung Details
Alomfilimab KY-1044 Phase 2 Clinical Kymab Liver Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Hepatocellular Details
Izuralimab XmAb-104; XmAb-23104 Phase 1 Clinical Xencor Nasopharyngeal Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Breast Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms Details
Acazicolcept ALPN-101 Phase 2 Clinical Alpine Immune Sciences, Abbvie Inc Graft vs Host Disease; Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Inflammation Details
Anti-ICOS (Bristol Myers Squibb) BMS-986226 Phase 1 Clinical Bristol-Myers Squibb Company Neoplasms Details
Feladilimab GSK-609; GSK-3359609 Phase 3 Clinical Glaxosmithkline Plc Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Multiple Myeloma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message